Caris Life Sciences, the Irving-based next-generation AI biotech company and precision medicine pioneer, has reached a new agreement with pharmaceutical giant Moderna to support Moderna’s oncology novel therapeutics initiatives.
Caris said that it’s creating and delivering innovative solutions to “revolutionize healthcare and improve the human condition” using molecular science and AI.
“We’re thrilled to partner with Moderna to impact and advance the field of cancer treatment with mRNA medicines, with a common goal of improving patient lives,” David Spetzler, president of Caris Life Sciences, said in a statement. “The aggregate strength of our combined molecular, data science, and therapeutics technologies will support the predictive modeling of patient responses to therapies, and more generally, may help improve the probability of technical and regulatory success of Moderna’s innovative medicines.”
Caris said that via this multiyear agreement, Moderna will leverage Caris’ extensive library of de-identified, multimodal data solutions derived from whole exome sequencing, whole transcriptome sequencing, and protein analyses, along with claims data to improve development strategies for Moderna’s oncology pipeline. That includes facilitation of optimal clinical trial design, discovery of novel biomarkers, and characterization of resistance mechanisms.
Leveraging Caris’ clinico-genomic database
“Partnering with Caris Life Sciences will support Moderna’s oncology portfolio with clinico-genomics data from Caris’ industry-leading and comprehensive suite of integrated precision medicine capabilities,” Praveen Aanur, MD, the oncology therapeutic area head of Moderna, said in a statement.
Caris said it has developed the largest clinico-genomic database coupled with cognitive computing to “unravel the molecular complexity of disease.”
The Irving company says it was the first in the industry to provide Whole Exome Sequencing DNA coverage and Whole Transcriptome Sequencing RNA coverage (WES / WTS) for every patient,.
Beyond Irving, Caris has offices in Phoenix, New York, Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia, and other international markets.
In January, Caris Life Sciences closed a senior secured term loan providing up to $400 million in capital from OrbiMed and Braidwell, bringing its funding total since 2018 to roughly $1.7 billion.
Get on the list.
Dallas Innovates, every day.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.